TY - JOUR
T1 - Change in biomarkers of type-2 inflammation following severe exacerbations of asthma
AU - Semprini, Ruth
AU - Shortt, Nick
AU - Ebmeier, Stefan
AU - Semprini, Alex
AU - Varughese, Rachel
AU - Holweg, Cecile T. J.
AU - Matthews, John G.
AU - Fingleton, James
AU - Weatherall, Mark
AU - Beasley, Richard
AU - Braithwaite, Irene
PY - 2019
Y1 - 2019
N2 - We investigated the time course of change of type-2 asthma biomarkers after a severe asthma exacerbation. Blood eosinophils were lowest immediately after treatment was initiated (0.07 vs 0.33×10 9 /L, p<0.001) while serum IgE levels were at their highest (339 vs 249 U/L, p<0.001). Fractional exhaled Nitric Oxide levels were lowest 2 weeks after treatment (23 vs 33 ppb, p=0.06) and serum periostin levels were lowest 1 week after treatment (45·9 vs 50·9 ng/mL, p<0.001). A delay of 4-8 weeks following a severe exacerbation is required if these biomarkers are used to guide the ongoing management of patients with asthma. Trial registration number Post-results; The Australia New Zealand Trial Registry, >ACTRN12614000443695.
AB - We investigated the time course of change of type-2 asthma biomarkers after a severe asthma exacerbation. Blood eosinophils were lowest immediately after treatment was initiated (0.07 vs 0.33×10 9 /L, p<0.001) while serum IgE levels were at their highest (339 vs 249 U/L, p<0.001). Fractional exhaled Nitric Oxide levels were lowest 2 weeks after treatment (23 vs 33 ppb, p=0.06) and serum periostin levels were lowest 1 week after treatment (45·9 vs 50·9 ng/mL, p<0.001). A delay of 4-8 weeks following a severe exacerbation is required if these biomarkers are used to guide the ongoing management of patients with asthma. Trial registration number Post-results; The Australia New Zealand Trial Registry, >ACTRN12614000443695.
UR - https://hdl.handle.net/1959.7/uws:64429
U2 - 10.1136/thoraxjnl-2018-211657
DO - 10.1136/thoraxjnl-2018-211657
M3 - Article
SN - 0040-6376
VL - 74
SP - 95
EP - 98
JO - Thorax
JF - Thorax
IS - 1
ER -
